Literature DB >> 9588908

Transgenic mice model of ocular neovascularization driven by vascular endothelial growth factor (VEGF) overexpression.

L Lakatos.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588908      PMCID: PMC1858588     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  5 in total

1.  Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine.

Authors:  T Matsubara; R Saura; K Hirohata; M Ziff
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

2.  D-penicillamine and retinopathy of prematurity.

Authors:  L Lakatos
Journal:  Pediatrics       Date:  1988-12       Impact factor: 7.124

Review 3.  Vascular endothelial growth factor and ocular neovascularization.

Authors:  J W Miller
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

4.  Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization.

Authors:  N Okamoto; T Tobe; S F Hackett; H Ozaki; M A Vinores; W LaRochelle; D J Zack; P A Campochiaro
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

5.  Control of peptide disulfide regioisomer formation by mixed cysteine-penicillamine bridges. Application to endothelin-1.

Authors:  J T Hunt; V G Lee; E C Liu; S Moreland; D McMullen; M L Webb; M Bolgar
Journal:  Int J Pept Protein Res       Date:  1993-09
  5 in total
  2 in total

Review 1.  Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions.

Authors:  C Emanueli; P Madeddu
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

2.  The effects of D-penicillamine on a murine model of oxygen-induced retinopathy.

Authors:  R Michael Siatkowski; Tammy L Yanovitch; John D Ash; Annie Moreau
Journal:  J AAPOS       Date:  2011-08       Impact factor: 1.220

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.